Middle East IVD Market - Opportunity Analysis and Industry Forecast (2024-2031)
Meticulous Research®, a leading global
market research company, published a research report titled, ‘Middle East IVD Market by Offering (Kits,
Software), Technology (Immunoassay, Molecular Diagnostics [PCR, NGS,
Microarray], Rapid Tests, Biochemistry), Application (Infectious Diseases,
Oncology), Diagnostic Approach (Lab) - Forecast to 2031.’
According to this latest publication from
Meticulous Research®, the Middle East In Vitro Diagnostics (IVD) market is expected to
reach $2.15 billion by 2031 at a CAGR of 4.1%
from 2024 to 2031. The growth of the Middle East IVD market is attributed
to the rising prevalence of chronic and infectious diseases, the growing demand
for point-of-care (PoC) and rapid diagnostics, rising healthcare expenditures,
growth in the aging population, and rising awareness about healthcare. However,
high prices for IVD tests and the variance in test results observed in rapid
IVD tests restrain the growth of the IVD market.
The rising awareness regarding early disease
diagnosis and increasing inclination toward personalized medicine in the UAE
and Saudi Arabia are expected to create growth opportunities for the players
operating in this market. However, the concerns pertaining to false positive
results in immunoassays and POC are a major challenge for market growth.
Key Players
The key players operating in the Middle East
IVD market are Abbott Laboratories (U.S.), Becton, Dickinson and Company
(U.S.), BioMérieux S.A. (France), Danaher Corporation (U.S.), F. Hoffmann-La
Roche (Switzerland), QIAGEN N.V. (Netherlands), Siemens Healthineers AG
(Germany), Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc.
(U.S.), Illumina, Inc. (U.S.), QuidelOrtho Corporation. (U.S.), Agilent
Technologies, Inc. (U.S.), and DiaSorin S.p.A. (Italy).
Middle East IVD Market: Future Outlook
The Middle East IVD market is segmented by
Offering (Kits & Reagents, Instruments, and Software & Services),
Technology (Immunoassay/Immunochemistry, Biochemistry/Clinical Chemistry,
Molecular Diagnostics, Point of Care (POC) Diagnostics, Whole Blood Glucose
Monitoring, Microbiology, Hematology, Coagulation/Hemostasis, Urinalysis, and
Other Technologies), Application (Infectious Diseases, Oncology, Diabetes,
Cardiology, Nephrology, Autoimmune Disorders, and Other Applications),
Diagnostic Approach (Lab Testing, OTC/Self-testing, and Point of Care Testing),
and End User (Diagnostic Laboratories, Hospitals & Clinics, Home
Healthcare, and Other End Users), and Countries. The study also evaluates
industry competitors and analyzes their market share at the country level.
Among all offerings studied
in this report, the kits & reagents segment is expected to register the
highest CAGR over the forecast period. The highest CAGR of this segment is
attributed to the frequent use of reagents and kits in the detection of various
chronic and infectious diseases, the wide commercial availability of a diverse
range of reagents and consumables for the diagnosis of various diseases, the
increase in the volume of testing for infectious diseases such as HIV and
influenza, and the growing awareness about self-testing among the general
population. According to UNAIDS, global HIV prevalence is decreasing, but the
Middle East and North Africa are one of the few regions where new HIV
infections are increasing at a rapid rate. In 2022, only 67% of people living
with HIV knew their HIV-positive status.
Among all technologies
studied in this report, in 2024, the molecular diagnostic
segment is expected to account for the largest share of the Middle East IVD
market. The large market share of this segment is attributed to the high
prevalence of communicable and non-communicable diseases requiring molecular
diagnostics (molecular diagnostic tests give more access to high-volume testing
in less time and better specificity) and increasing the adoption of molecular
diagnostic techniques in hospitals and laboratories.
Among all applications
studied in this report, in 2024, the infectious disease segment
is expected to account for the largest share of the Middle East IVD market.
Infectious diseases are further categorized into respiratory infections
(excluding influenza), hepatitis, HIV, HAIs, tropical diseases, influenza,
sexually transmitted diseases (STDs), and other infectious diseases. The
increasing prevalence of seasonal influenza and sexually transmitted diseases
(STDs) is increasing the demand for IVD testing. For instance, people aged over
65 years account for approximately 50-70% of hospitalizations & 90% of
influenza-related deaths.
Among all diagnostic
approaches studied in this report, the point-of-care testing segment is
expected to grow at the highest CAGR during the forecast period. The growth of
the POC testing segment is attributed to the increasing prevalence of chronic
diseases, the launch of PoC tests by market players, and the lack of skilled
technicians for performing lab tests. Additionally, the launch of PoC testing
in the region is contributing to the growth of this segment.
Among all end users studied
in this report, in 2024, the hospitals & clinics segment is expected to
account for the largest share of the Middle East IVD market. Hospitals and
clinics perform a wide range of tests to diagnose various medical conditions,
including communicable and non-communicable diseases. Hospitals in urban and
rural areas provide large populations with access to diagnosis. Also, there was
a significant increase in hospital admissions due to a rise in the rate of
infectious diseases, which boosted the demand for diagnostic products.
Geographic Review
This research report comprehensively analyzes
major countries: Saudi Arabia, UAE, Qatar, Kuwait, Oman, Israel, and the rest
of the Middle East. In 2024, Saudi Arabia is expected to account for the
largest share of the Middle East IVD market. The largest share of the country
is attributed to the growing aging, rising chronic and infectious diseases, and
the increasing adoption of self-testing. Additionally, rising healthcare
expenditure is increasing the demand for IVD. The healthcare expenditure in
Saudi Arabia is rising. The Government of Saudi Arabia has implemented various
reforms under the “Vision 2030” strategy to improve the business environment
and sectors, including healthcare. Saudi Arabia spent an estimated 6.6% of its
GDP on healthcare expenditure in 2021, which is 3.7% higher than the healthcare
expenditure a decade ago. Healthcare expenditure in Saudi Arabia is expected to
increase at an annual average of 3.0% from 2022 to 2025 to meet “Vision 2030”
goals.
Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=5764
Key questions answered in the
report:
· Which are
the high-growth market segments in terms of the offering, technology,
application, diagnostic approach, end user, and country?
· What was
the historical market for IVD testing in the Middle East?
· What are
the market forecasts and estimates for the period 2024–2031?
· What are
the major drivers, restraints, challenges, and opportunities in the Middle East
IVD market?
· Who are the
major players in the Middle East IVD market?
Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Comments
Post a Comment